 Fimasartan BR-A-657-K, a selective blocker of AT1 receptor subtype, showed the rapid and potent antihypertensive effect in many hypertensive models. Phase I study, Fimasartan BR-A-657-K 20mg 480mg single dosing with healthy subjects, demonstrated that the Fimasartan BR-A-657-K was very safe and well tolerated. Another phase I study, Fimasartan BR-A-657-K 120mg and 360mg dosing for 7 days, also showed that Fimasartan BR-A-657-K was safe and tolerable though one temporal adverse event was observed in high dose. 